BioSpace News Archive

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2020 financial results on Monday, May 11, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 11, 2020. The financial results and live webcast will be accessible through the Investor Relations section of the Compan

Prothena Corporation plc (NASDAQ:PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held on Tuesday, May 19, 2020

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the first quarter 2020 after 5:00 p.m. ET on Tuesday, May 5, 2020.

This week, Methodist Le Bonheur Healthcare announced it is participating in Mayo Clinic’s Expanded Access Protocol for Convalescent Plasma Program for treatment of patients with COVID-19.

Buildings temporarily closed due to COVID-19 present an increased risk for waterborne pathogens like Legionella which can cause Legionnaires’ Disease.

Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial and operating results for the year ended December 31, 2019.

Hebron Technology Co., Ltd. (“Hebron” or the “Company”) (Nasdaq: HEBT), a technology oriented enterprise group conducting business in the pharmaceutical equipment and engineering industry segment and financial service industry segment, today announced its financial results for the fiscal year ended December 31, 2019.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced the closing of the Company’s previously announced underwritten public offering of 210,833,334 shares of common stock (or common stock equivalents in lieu thereof) at an effective public offering price of $0.15 per share of common stock

Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network, conducted an observational real world study of more than 3,000 hospitalized COVID-19 patients and found that hypertension, the most common co-existing condition, does not have a major impact on survival from the infection when adjusted for age and other comorbid conditions.

Marrone Bio Innovations, Inc. (Nasdaq: MBII) (the “Company”) today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company of its noncompliance with Nasdaq Listing Rule 5550(a)(2) as a result of the company’s closing bid price being below $1.00 per share for 30 consecutive days.